(Q44621693)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23637027%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

title

Autologous hematopoietic stem cell transplantation as a treatment option for aggressive multiple sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23637027%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23637027%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Roland Martin

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23637027%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

Riccardo Saccardi

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23637027%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

publication date

1 June 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23637027%20AND%20SRC:MED&resulttype=core&format=json

Current treatment options in neurology

29 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23637027%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23637027%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23637027%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

270-280

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23637027%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11940-013-0234-9

29 February 2020

exact match

0 references

cites work

Environmental factors and multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0234-9

Vitamin D and multiple sclerosis: epidemiology, immunology, and genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0234-9

Autologous haematopoietic stem-cell transplantation in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0234-9

Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0234-9

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0234-9

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0234-9

A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0234-9

Age and disability accumulation in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0234-9

Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0234-9

Multiple sclerosis conference synopsis and discussion: cellular therapy for treatment of autoimmune diseases (October 2005).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0234-9

Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0234-9

Immune ablation followed by autologous hematopoietic stem cell transplantation for the treatment of poor prognosis multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0234-9

Autologous hematopoietic stem cell transplantation for autoimmune disease--is it now ready for prime time?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0234-9

Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0234-9

Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0234-9

Brazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAM/horse ATG and CY/rabbit ATG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0234-9

Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0234-9

Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0234-9

Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0234-9

Disease progression after bone marrow transplantation in a model of multiple sclerosis is associated with chronic microglial and glial progenitor response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0234-9

No proinflammatory signature in CD34+ hematopoietic progenitor cells in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-013-0234-9

Thymic export function and T cell homeostasis in patients with relapsing remitting multiple sclerosis

21 January 2018

1 reference

12 December 2020

Renewing the T cell repertoire to arrest autoimmune aggression

1 reference

12 December 2020

CD34+ selected autologous peripheral blood stem cell transplantation for multiple sclerosis: report of toxicity and treatment results at one year of follow-up in 15 patients

1 reference

12 December 2020

Autologous stem cell transplantation for progressive multiple sclerosis: Update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database

1 reference

12 December 2020

Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience

1 reference

12 December 2020

Recent immune status determines the source of antigens that drive homeostatic T cell expansion

1 reference

12 December 2020

Autologous hematopoietic stem cell transplantation for multiple sclerosis--if confused or hesitant, remember: 'treat with standard immune suppressive drugs and if no inflammation, no response'

1 reference

12 December 2020

Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT

1 reference

12 December 2020

Clinical and MRI outcome after autologous hematopoietic stem cell transplantation in MS

1 reference

12 December 2020

Tolerance induction by bone marrow transplantation in a multiple sclerosis model

1 reference

12 December 2020

Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation

1 reference

12 December 2020